CY1122131T1 - Γενετικη ανοσοποιηση για την παραγωγη ανοσοσφαιρινων κατα των κυτταρο-σχετιζομενων αντιγονων, οπως τα ρ2χ7, cxcr7 ή cxcr4 - Google Patents

Γενετικη ανοσοποιηση για την παραγωγη ανοσοσφαιρινων κατα των κυτταρο-σχετιζομενων αντιγονων, οπως τα ρ2χ7, cxcr7 ή cxcr4

Info

Publication number
CY1122131T1
CY1122131T1 CY20191100439T CY191100439T CY1122131T1 CY 1122131 T1 CY1122131 T1 CY 1122131T1 CY 20191100439 T CY20191100439 T CY 20191100439T CY 191100439 T CY191100439 T CY 191100439T CY 1122131 T1 CY1122131 T1 CY 1122131T1
Authority
CY
Cyprus
Prior art keywords
associated antigens
against cell
immunoglobulin sequences
antigens
specifically
Prior art date
Application number
CY20191100439T
Other languages
English (en)
Inventor
Toon Laeremans
Catelijne Stortelers
Friedrich Nolte
Maria Gonzalez
Joana Assuncao
Philippe Van Rompaey
Original Assignee
Ablynx N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx N.V. filed Critical Ablynx N.V.
Publication of CY1122131T1 publication Critical patent/CY1122131T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μία μέθοδο για την παραγωγή αλληλουχιών ανοσοσφαιρινών κατά των κυτταρο-σχετιζόμενων αντιγόνων, πιο συγκεκριμένα των αντιγόνων που είναι αγκυρωμένα σε μεμβράνη. Η εφεύρεση παρέχει, επίσης, αλληλουχίες ανοσοσφαιρινών που μπορούν να ληφθούν με τη μέθοδο της εφεύρεσης. Πιο συγκεκριμένα, η παρούσα εφεύρεση αναφέρεται στην παραγωγή αλληλουχιών ανοσοσφαιρινών χρησιμοποιώντας τον εμβολιασμό με DNA. Πιο συγκεκριμένα, η παρούσα εφεύρεση αναφέρεται στην παραγωγή αλληλουχιών ανοσοσφαιρινών στις καμηλίδες, που κατευθύνονται, κατά προτίμηση, κατά των κυτταρο-σχετιζόμενων αντιγόνων, και συγκεκριμένα κατά των αντιγόνων με μεμβρανικές επικράτειες πολλαπλής διαπέρασης, συμπεριλαμβανομένων των GPCR και των ιοντικών διαύλων, μέσω εμβολιασμού με DNA. Επιπλέον, η παρούσα εφεύρεση αναφέρεται στις εν λόγω αλληλουχίες ανοσοσφαιρινών κατά των κυτταρο-σχετιζόμενων αντιγόνων, και πιο συγκεκριμένα κατά των αντιγόνων που είναι αγκυρωμένα σε μεμβράνη, όπως είναι, π.χ., οι GPCR και οι ιοντικοί δίαυλοι, και κατά μεγαλύτερη προτίμηση οι ιοντικοί δίαυλοι.
CY20191100439T 2008-12-19 2019-04-22 Γενετικη ανοσοποιηση για την παραγωγη ανοσοσφαιρινων κατα των κυτταρο-σχετιζομενων αντιγονων, οπως τα ρ2χ7, cxcr7 ή cxcr4 CY1122131T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20318808P 2008-12-19 2008-12-19
PCT/EP2009/067687 WO2010070145A2 (en) 2008-12-19 2009-12-21 Method for generation of immunoglobulin sequences

Publications (1)

Publication Number Publication Date
CY1122131T1 true CY1122131T1 (el) 2020-11-25

Family

ID=42269156

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100439T CY1122131T1 (el) 2008-12-19 2019-04-22 Γενετικη ανοσοποιηση για την παραγωγη ανοσοσφαιρινων κατα των κυτταρο-σχετιζομενων αντιγονων, οπως τα ρ2χ7, cxcr7 ή cxcr4

Country Status (11)

Country Link
US (2) US9260508B2 (el)
EP (2) EP3470425A3 (el)
JP (2) JP2012512646A (el)
CN (2) CN102257003B (el)
AU (2) AU2009329501B2 (el)
CA (1) CA2747644C (el)
CY (1) CY1122131T1 (el)
DK (1) DK2370465T3 (el)
ES (1) ES2729320T3 (el)
HU (1) HUE042919T2 (el)
WO (1) WO2010070145A2 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
HUE042919T2 (hu) 2008-12-19 2019-07-29 Ablynx Nv Genetikai immunizáció sejthez kapcsolódó antigének - például P2X7, CXCR7 vagy CXCR4 - elleni immunglobulinok elõállítására
WO2011083141A2 (en) * 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
WO2011117423A1 (en) * 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
BR112013011003B1 (pt) 2010-11-08 2021-12-07 Novartis Ag Polipeptídeo e seus usos, célula hospedeira transgênica de microrganismo, nanocorpo monovalente, bivalente, multivalente, biparatópico ou multiparatópico, e composição farmacêutica
PL2686347T3 (pl) * 2011-03-16 2018-10-31 Argenx Bvba Przeciwciała przeciwko CD70
CA2831415A1 (en) * 2011-03-28 2012-10-04 Ablynx Nv Bispecific anti-cxcr7 immunoglobulin single variable domains
EP2760892A1 (en) 2011-09-29 2014-08-06 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
US10946104B2 (en) 2012-01-13 2021-03-16 Apo-Tb.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
EP2855518A1 (en) * 2012-06-01 2015-04-08 Ablynx N.V. P2x7 receptor antagonists and agonists
US20150175683A1 (en) * 2012-06-26 2015-06-25 Apo-T B.V. Binding molecules targeting pathogens
AU2014211355B2 (en) 2013-01-30 2017-07-13 Vib Vzw Novel chimeric polypeptides for screening and drug discovery purposes
PT2953973T (pt) 2013-02-05 2019-10-25 Univ Brussel Vrije Agentes de ligação do receptor muscarínico de acetilololina e usos
GB2517953A (en) * 2013-09-05 2015-03-11 Argen X Bv Antibodies to complex targets
WO2015121092A1 (en) 2014-01-30 2015-08-20 Vib Vzw Opioid receptor binding agents and uses thereof
WO2016012363A1 (en) 2014-07-22 2016-01-28 Vib Vzw Methods to select for agents that stabilize protein complexes
CN104479016A (zh) * 2014-12-31 2015-04-01 广州吉赛生物科技有限公司 利用dna纹身免疫制备抗体的方法
WO2017081265A1 (en) * 2015-11-12 2017-05-18 Ablynx Nv Improved p2x7 receptor binders and polypeptides comprising the same
EP3833387A4 (en) * 2018-08-27 2022-05-11 University of Virginia Patent Foundation COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRUS INFECTION
US11312754B2 (en) * 2019-05-31 2022-04-26 Access Business Group International Llc Sunflower seed protein-derived peptides
JPWO2021006212A1 (el) * 2019-07-08 2021-01-14
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
WO2022235584A1 (en) * 2021-05-03 2022-11-10 Twist Bioscience Corporation Variant nucleic acid libraries for glycans
US20220356468A1 (en) * 2021-05-03 2022-11-10 Twist Bioscience Corporation Variant nucleic acid libraries for ion channels
CN118255888A (zh) * 2023-08-31 2024-06-28 恺佧生物科技(上海)有限公司 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
JP3810791B2 (ja) 1993-09-10 2006-08-16 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 緑色蛍光タンパク質の使用
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
WO1996022307A1 (en) 1995-01-19 1996-07-25 The Research Foundation Of State University Of New York Genes encoding an insect calcium channel
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5693492A (en) 1995-05-05 1997-12-02 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
EP0851874B1 (en) 1995-09-22 1999-09-15 Novo Nordisk A/S Novel variants of green fluorescent protein, gfp
US6027881A (en) 1996-05-08 2000-02-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
WO1998021355A1 (en) 1996-11-15 1998-05-22 Life Technologies, Inc. Mutants of green fluorescent protein
CN1203178C (zh) 1997-10-27 2005-05-25 尤尼利弗公司 多价抗原结合蛋白
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU2291700A (en) 1999-01-19 2000-08-07 Unilever Plc Method for producing antibody fragments
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
EP1328626B1 (en) 2000-05-26 2013-04-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
PT1360203E (pt) * 2001-01-17 2009-04-03 Intreat Pty Ltd Anticorpos de receptor p2x7 não funcional para diagnóstico e tratamento de cancros e outros estados
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
AU2002351896A1 (en) * 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
CA2471116A1 (en) 2001-12-21 2003-07-03 Serge Muyldermans Method for cloning of variable domain sequences
JP2005517674A (ja) 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
JP4603894B2 (ja) 2002-12-03 2010-12-22 ユセベ ファルマ ソシエテ アノニム 抗体産生細胞を同定するためのアッセイ
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
WO2004060965A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US7344860B2 (en) 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
GB0312321D0 (en) * 2003-05-29 2003-07-02 Astrazeneca Ab New combination
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
WO2005019824A1 (en) 2003-08-20 2005-03-03 Celltech R & D Limited Methods for obtaining antibodies
EP2251357A1 (en) 2003-11-07 2010-11-17 Ablynx N.V. Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor
US20060008601A1 (en) 2004-06-25 2006-01-12 Zeik Douglas B Flexible laminate having an integrated pressure release valve
KR101443473B1 (ko) 2004-07-22 2014-09-22 에라스무스 유니버시티 메디컬 센터 로테르담 Ｖh 결합 영역의 분리 방법
CA2583017A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
WO2006040154A2 (en) 2004-10-14 2006-04-20 Dublin City University Prokaryotic two hybrid system
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
WO2007042289A2 (en) 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
EP2040995A1 (en) 2006-06-26 2009-04-01 Aida Centre, S.L. Blister package integrating rfid based tags
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
EP2082032A4 (en) * 2006-10-10 2010-06-30 Biosceptre Int Ltd ANTIBODIES AGAINST NON-FUNCTIONAL P2X7 RECEPTOR PRODUCING HYBRIDOMES
EP2557090A3 (en) 2006-12-19 2013-05-29 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
AU2008328781A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
HUE042919T2 (hu) 2008-12-19 2019-07-29 Ablynx Nv Genetikai immunizáció sejthez kapcsolódó antigének - például P2X7, CXCR7 vagy CXCR4 - elleni immunglobulinok elõállítására
EP2855518A1 (en) * 2012-06-01 2015-04-08 Ablynx N.V. P2x7 receptor antagonists and agonists

Also Published As

Publication number Publication date
CN102257003A (zh) 2011-11-23
AU2009329501A1 (en) 2010-06-24
JP2012512646A (ja) 2012-06-07
EP2370465A2 (en) 2011-10-05
US10023633B2 (en) 2018-07-17
US20160264664A1 (en) 2016-09-15
WO2010070145A3 (en) 2010-12-02
AU2016200146A1 (en) 2016-02-04
JP6034435B2 (ja) 2016-11-30
EP3470425A3 (en) 2019-07-17
US20100173799A1 (en) 2010-07-08
EP3470425A2 (en) 2019-04-17
CN102257003B (zh) 2017-04-05
AU2009329501B2 (en) 2015-11-26
DK2370465T3 (da) 2019-05-06
EP2370465B1 (en) 2019-01-23
US9260508B2 (en) 2016-02-16
CA2747644C (en) 2023-01-24
AU2016200146B9 (en) 2018-02-15
JP2015155429A (ja) 2015-08-27
CN107011434A (zh) 2017-08-04
HUE042919T2 (hu) 2019-07-29
WO2010070145A2 (en) 2010-06-24
CN107011434B (zh) 2021-02-19
CA2747644A1 (en) 2010-06-24
AU2016200146B2 (en) 2018-02-01
ES2729320T3 (es) 2019-10-31

Similar Documents

Publication Publication Date Title
CY1122131T1 (el) Γενετικη ανοσοποιηση για την παραγωγη ανοσοσφαιρινων κατα των κυτταρο-σχετιζομενων αντιγονων, οπως τα ρ2χ7, cxcr7 ή cxcr4
CY1118970T1 (el) Στελεχη shigella με υπερφλυκταινωση
CY1124120T1 (el) ΜΕΘΟΔΟΣ ΓΙΑ ΠΑΡΑΓΩΓΗ ΤΕΤΡΑΦθΟΡΟΠΡΟΠΕΝΙΩΝ
CY1124888T1 (el) Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii-fc και μεθοδοι χρησεως αυτων
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CY1122036T1 (el) Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα
CY1121431T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για τον ανθρωπινο οχ40
CY1123959T1 (el) Μεθοδος και συνθεσεις για την κυτταρικη ανοσοθεραπεια
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1118303T1 (el) Συγκεκριμενο για διασταυρουμενα-ειδη δι-συγκεκριμενο αντισωμα μονης-αλυσου psmaxcd3
CY1119893T1 (el) Προϊοντα συζευξης cc-1065 αναλογων και διλειτουργικων συνδετων
CY1112105T1 (el) Ανοσογονα βακτηριακα κυστιδια με πρωτεϊνες εξωτερικης μεμβρανης
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
CY1116226T1 (el) Χρηση toy rna για επαναπρογραμματισμο σωματικων κυτταρων
CY1120055T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
CY1117718T1 (el) Διπλα ειδικα απλης αλυσου αντισωματα με ειδικοτητα για υψηλου μοριακου βαρους αντιγονα στοχους
NZ703581A (en) Anti-cd70 antibody drug conjugates
MX2020013977A (es) Proteínas quiméricas transmembrana y usos de las mismas.
CY1117896T1 (el) Εμβολιο πρωτεϊνης συντηξης
CY1116940T1 (el) Φλυκταινες εμπλουτισμενες σε φωσφολιπιδιο που φερουν παραγοντα ιστου εχουσες αιμοστατικες δραστικοτητες και χρησεις αυτων
BR112017014031A2 (pt) n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado.
JP2015525065A5 (el)
CY1122132T1 (el) Μεθοδοι για τη μειωση των ρυθμων εξαρσης του ασθματος με χρηση μπενραλιζουμαμπης
EA201792442A1 (ru) Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение